Pfizer (PFE) stock fell slightly on Tuesday despite reporting an earnings beat and upbeat guidance. The pharmaceutical company said it saw operational revenue growth contributions from several treatments, including Eliquis, Paxlovid, the Vyndaqel family, Nurtec, and Lorbrena, during the quarter, though its COVID-19 products declined.
In the earnings call, Pfizer said it expects to spend $10.8 billion-$11.8 billion on research and development this year, particularly on developing its oncology and obesity pipeline. Pfizer is working on berobenatide, a GLP-1 injectable administered only once a month rather than weekly, as well as several cancer drugs.
“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value,” CEO Albert Bourla said in a release. “Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline.”
In the third quarter, Pfizer reported revenue was little changed year over year at $16.6 billion, ahead of analyst estimates of $15.9 billion, according to S&P Global Market Intelligence. Earnings per share came in at $0.56, beating Wall Street’s estimates of $0.48 per share.
Pfizer lifted its full-year revenue guidance to a range of $62 billion to $64 billion, up from $60.5 billion to $62.5 billion previously. The company also raised and narrowed its 2026 earnings per share guidance to $2.95 to $3.05.
30.44 -0.24 (-0.77%)
As of 1:16:31 PM EST. Market Open.



GIPHY App Key not set. Please check settings